Background. Blastomycosis is a commonly misdiagnosed infection caused by
Blastomyces spp. It is not reportable in New York State (NYS), but where reportable, yearly incidence is 1-2/100,000 persons. In October 2017, a physician notified the NYS Department of Health (NYSDOH) of six blastomycosis cases seen during April 2016-July 2017 in the nonendemic eastern upstate area known as the Capital District (CD). NYSDOH investigated to determine the possibility of locally acquired blastomycosis.
Methods. NYS hospital blastomycosis discharge codes from the January 2007-December 2016 Statewide Planning and Research Cooperative System dataset were reviewed. To better understand illness in the area of highest incidence, NYSDOH contacted CD physicians to identify patients diagnosed with blastomycosis during April 2016-February 2018. Chart reviews and interviews were conducted to obtain travel and disease progression details.
Results. During 2007 During -2016 , there were 279 blastomycosis diagnoses in NYS. Mean annual blastomycosis diagnoses during 2007-2015 was 24 (incidence: 0.1/100,000 persons); in 2016, there were 59 blastomycosis diagnoses (incidence: 0.3/100,000 persons). A CD county had the highest state incidence, with a rate increase from 2.0/100,000 persons during 2007-2015 to 4.1/100,000 persons during 2016. CD physicians provided contact and clinical information for the six initially-identified patients and two additional patients seen during April 2016-February 2018. All experienced delays in diagnosis, seven lacked travel history, two had cutaneous blastomycosis, three had pulmonary blastomycosis, and three had disseminated blastomycosis. One died from blastomycosis and another required long-term ventilator support. Seven cases were identified by culture or histopathology; the diagnostic method for one was unknown.
Conclusion. One CD county had blastomycosis rates similar to known endemic areas; patients lacked travel history to endemic areas, indicating locally acquired blastomycosis might have occurred. To improve prompt diagnosis, NYS clinicians and laboratorians should consider blastomycosis in patients with pneumonia, even without travel history to endemic areas. Further evaluation is needed to determine whether the endemic area of NYS has expanded.
Disclosures. All authors: No reported disclosures. Methods. Patients of all age groups with a positive Candida spp. blood culture from January 2012 to December 2017. Only initial episodes was accounted per patient. Demographic data was retrospectively collected and analyzed. Between-group differences were compared using Chi2, logistic regression used to calculate odds ratios, and survival analysis using Kaplan Meier.
Candida Bloodstream Infections in a Tertiary
Results. 243 episodes of Candida spp. BSI occurred during the study period, increasing over time. A median 21 days of hospital stay to the first episode of candidemia . Candida albicans represented 51% of episodes, followed by C. parapsilosis 27%, C. glabrata 9%, C. tropicalis 9%, C. haemulonii 1.6%, C. krusei, C. pelliculosa, C. guilllermondi. Male sex predominated (62%) over females (38%), median age was 54 years. Age group distribution corresponded to 23 newborns (9%), 6 adolescents (3%), 141 adults (58%), and 72 elders (30%). Surgical wards and surgical ICU comprised for 47% of cases. Admission for intraabdominal pathology; 35% of cases, followed by cancer 21% (63% solid tumors, 37% hematologic malignancies), 11% trauma and orthopedic surgery. Overall resistance rates were 14% fluconazole, 5% voriconazole and 8% for amphotericin B, no resistance to echinocandins detected. Overall mortality was 69%. Mortality by species C. krusei 100%, C. tropical 95%, C. glabrata 81%, C. albicans 68%, C. parapsilosis 59%, C. haemulonii 50%, (P = 0.02). No fatalities occurred with C. pelliculosa and C. guillermondi. Mortality was highest in elderly (69%), followed by adults (65%) and adolescents (50%) (P = 0.039). Death OR was 2.13 for elders vs. the adult group (P = 0.02, CI 1.097-4.155). A negative correlation was documented between age group and survival (rho -0.3250 P < 0.00001).
Conclusion. Candida BSI show an increasing trend over time in our cohort. Candida parapsilosisis as the second cause of candidemia displays lower mortality than its counterparts. Mortality was higher than previously reported and is highest in the elderly. Antimicrobial stewardship programs, source control in abdominal surgeries and appropriate central venous catheter use need to be implemented to improve outcomes.
Disclosures. All authors: No reported disclosures. Background. Obese patients may have altered pharmacokinetic parameters when compared with normal weight patients due to their body habitus and altered drug clearance. Case reports suggest higher echinocandin dosing may be needed to reach adequate serum concentrations in obese patients. The purpose of this project is to compare patient outcomes between normal weight and overweight patients that receive an echinocandin for candidemia.
Impact of Obesity in Patients With
Methods. IRB approved, retrospective cohort at five hospitals with an antimicrobial stewardship program. Dates: January 1, 2014-January 31, 2018. Included: ≥18 years, Candida species positive blood culture or T2MR, anidulafungin FDA label dose for ≥72 hours. Exclusion criteria: neutropenia, endocarditis, osteomyelitis, meningitis, immunosuppression. Primary outcome: 30-day all-cause mortality. Secondary outcomes: 14-day global clinical cure rates, Candida eye involvement, recurrence, antifungal restart, and optimal azole dose.
Results. One hundred seventy-three patients included: 121 blood; 73 T2MR. Obese: more female, pulmonary disease. Underweight: less surgery. Most common species: C. albicans (33%), C. glabrata (33%). More C. parapsilosis in obese (36.4%). Low anidulafungin minimum inhibitory concentrations (MIC) in all groups, but elevated in C. parapsilosis. No association between body mass index and mortality: underweight (36.4%), normal (25.8%), overweight (32.0%), obese (33.9%), morbidly obese (31.8%). See Table 1 for variables associated with mortality. No differences in quality of management, recurrence, Candida eye involvement, antifungal restart, optimal azole dose. More global cure in survivors.
Conclusion. We were unable to detect a difference in mortality in patients with candidemia by weight group. Line removal and receipt of ≥5 days of anidulafungin were protective. Background. Candidemia is often hospital acquired. With the inpatient-outpatient shift in healthcare, many cases are acquired in the community. We present a review of community-acquired candidemia.
Community-Onset Candidemia: Trends Over 7 Years
Methods. We reviewed blood culture results (January 1, 2010-December 31, 2017), selected patients with candidemia, defined the place of onset (community onset [CO]: 0-3 days after admission; hospital onset [HO]: ≥4 days), the source and species distribution and compared CO and HO cases.
Results. We encountered 210 candidemia episodes. The rate of candidemia (0.6-1.2/1,000 discharges) and species distribution fluctuated without a clear trend. CO accounted for 92 (43.8%) episodes including 83 healthcare-related (CO-HC) and 9 (4.3%) without healthcare exposure (CO-A). CO/HO proportion did not significantly change over time. Source and species distribution were similar in CO and HO cases except for higher proportion of intravenous drug users (IVDA), soft tissue/bone (STB) sources, and a trend toward more UTI in CO (table) . Comparison of cases with C. albicans and C. glabrata revealed that C. glabrata was more common in diabetics (51.5 vs. 33.0%; P = 0.005), and hemodialysis-dependent (H-D) cases (63.6% vs. 38.5; P = 0.04), and tended to be less common in UTI (25.9% vs. 45 .4% in other sources; P = 0.09).
Conclusion. Candidemia remains a healthcare-related event but a significant portion is CO. CO-A is limited to IVDA and patients with comorbidities. Sources and species distribution was similar in CO-HC and HO cases except for more UTI in CO-HC. C. albicans remained more common but C. glabrata surpassed C. albicans among diabetics and H-D. Background. Early initiation of empiric antifungal therapy has been shown to decrease morbidity and mortality among patients with candidemia/invasive candidiasis (C/IC). However, the initiation of appropriate antifungal therapy is frequently delayed due to the severe limitations in early diagnosis. The goal of this study is to develop a high-risk scoring system to identify patients who may be eligible for preemptive antifungal therapy. The proposed new methodology combines hybrid modeling and blockchain technology.
Methods. Our approach is novel and using expert physicians' perception of C/ IC risk factors with those described in the hospitals through a set of models (hybrid model building from primary and secondary data). The goal is to improve the early detection of C/IC and initiate antifungal therapy. Once candidate hybrid models are derived, blockchain technology will be utilized. The methodology is based on vectors consisting of the ranking of candidiasis risk factors. These vectors will be constructed based on expert clinicians rank scores of known risk factors. Such methods are different than the usual statistical rank correlation computations, such as Spearman's rank correlation, etc
Results. Preliminary analysis suggests threepotential models. Model 1: uses the following order of variables, by their relative importance: (1) major surgery within 0-3 days, (2)TPN-7-3 days, (3) steroids 0-3 days, (4) ECMO, (5) hemodialysis 0-3 days, (6) diabetes mellitus. Model 2 includes: (1)multifocal Candida colonization, 2.) central venous catheter 0-3 days, (3) LVAD, (4) medical ICU, (5) APACHE score > 20, (6) mechanical ventilation. Model 3 includes (1) pancreatitis -710 days, (2) diabetes mellitus, (3) hemodialysis 0-3 days, (4) central venous catheter 0-3 days, (5) TPN-7-3 days, 6.) APACHE score > 20.
Conclusion. Blockchain methods we propose are some of the first of their kind used in health research and are very suitable for the early detection of C/IC and other diseases where preemptive therapy is necessary. The following step will be to verify and use these models in the clinical realm and verify their effects on outcomes. Second we need to develop and evaluate our proposed methodology in building hybrid models,
